Targeted Bacterial Deletion Program

About Flightpath Biosciences

Flightpath Biosciences is pioneering a precision anti-infective approach to treat complex, infection-driven diseases by selectively deleting harmful bacteria without disrupting the commensal microbiome. Its core platform, Targeted Bacterial Deletion™, is being applied to a diverse pipeline targeting pathogens implicated in colorectal cancer, periodontal disease, inflammatory bowel disease, Lyme disease, bacterial vaginosis, and endometriosis. The company is in a pre-clinical to early clinical stage, having recently in-licensed assets to accelerate its pipeline, and operates as a private entity. Its strategy addresses the growing understanding of the microbiome's role in chronic inflammation, cancer, and systemic health.

About Flightpath Biosciences

Flightpath Biosciences is pioneering a precision anti-infective approach to treat complex, infection-driven diseases by selectively deleting harmful bacteria without disrupting the commensal microbiome. Its core platform, Targeted Bacterial Deletion™, is being applied to a diverse pipeline targeting pathogens implicated in colorectal cancer, periodontal disease, inflammatory bowel disease, Lyme disease, bacterial vaginosis, and endometriosis. The company is in a pre-clinical to early clinical stage, having recently in-licensed assets to accelerate its pipeline, and operates as a private entity. Its strategy addresses the growing understanding of the microbiome's role in chronic inflammation, cancer, and systemic health.

About Flightpath Biosciences

Flightpath Biosciences is pioneering a precision anti-infective approach to treat complex, infection-driven diseases by selectively deleting harmful bacteria without disrupting the commensal microbiome. Its core platform, Targeted Bacterial Deletion™, is being applied to a diverse pipeline targeting pathogens implicated in colorectal cancer, periodontal disease, inflammatory bowel disease, Lyme disease, bacterial vaginosis, and endometriosis. The company is in a pre-clinical to early clinical stage, having recently in-licensed assets to accelerate its pipeline, and operates as a private entity. Its strategy addresses the growing understanding of the microbiome's role in chronic inflammation, cancer, and systemic health.

About Flightpath Biosciences

Flightpath Biosciences is pioneering a precision anti-infective approach to treat complex, infection-driven diseases by selectively deleting harmful bacteria without disrupting the commensal microbiome. Its core platform, Targeted Bacterial Deletion™, is being applied to a diverse pipeline targeting pathogens implicated in colorectal cancer, periodontal disease, inflammatory bowel disease, Lyme disease, bacterial vaginosis, and endometriosis. The company is in a pre-clinical to early clinical stage, having recently in-licensed assets to accelerate its pipeline, and operates as a private entity. Its strategy addresses the growing understanding of the microbiome's role in chronic inflammation, cancer, and systemic health.

About Flightpath Biosciences

Flightpath Biosciences is pioneering a precision anti-infective approach to treat complex, infection-driven diseases by selectively deleting harmful bacteria without disrupting the commensal microbiome. Its core platform, Targeted Bacterial Deletion™, is being applied to a diverse pipeline targeting pathogens implicated in colorectal cancer, periodontal disease, inflammatory bowel disease, Lyme disease, bacterial vaginosis, and endometriosis. The company is in a pre-clinical to early clinical stage, having recently in-licensed assets to accelerate its pipeline, and operates as a private entity. Its strategy addresses the growing understanding of the microbiome's role in chronic inflammation, cancer, and systemic health.

About Flightpath Biosciences

Flightpath Biosciences is pioneering a precision anti-infective approach to treat complex, infection-driven diseases by selectively deleting harmful bacteria without disrupting the commensal microbiome. Its core platform, Targeted Bacterial Deletion™, is being applied to a diverse pipeline targeting pathogens implicated in colorectal cancer, periodontal disease, inflammatory bowel disease, Lyme disease, bacterial vaginosis, and endometriosis. The company is in a pre-clinical to early clinical stage, having recently in-licensed assets to accelerate its pipeline, and operates as a private entity. Its strategy addresses the growing understanding of the microbiome's role in chronic inflammation, cancer, and systemic health.

About Flightpath Biosciences

Flightpath Biosciences is pioneering a precision anti-infective approach to treat complex, infection-driven diseases by selectively deleting harmful bacteria without disrupting the commensal microbiome. Its core platform, Targeted Bacterial Deletion™, is being applied to a diverse pipeline targeting pathogens implicated in colorectal cancer, periodontal disease, inflammatory bowel disease, Lyme disease, bacterial vaginosis, and endometriosis. The company is in a pre-clinical to early clinical stage, having recently in-licensed assets to accelerate its pipeline, and operates as a private entity. Its strategy addresses the growing understanding of the microbiome's role in chronic inflammation, cancer, and systemic health.

Therapeutic Areas